Edition:
United Kingdom

Axogen Says Recon Study Will Support Submission Of Biologic License Application To FDA For Avance Nerve Graft


Monday, 22 Apr 2019 

April 22 (Reuters) - AxoGen Inc ::AXOGEN, INC. ANNOUNCES COMPLETION OF PLANNED INTERIM ANALYSIS AND ONE-TIME ENROLLMENT EXPANSION FOR RECON® STUDY.AXOGEN INC - STUDY WILL SUPPORT SUBMISSION OF A BIOLOGIC LICENSE APPLICATION (BLA) TO FDA FOR AVANCE NERVE GRAFT.AXOGEN INC - STUDY ENROLLMENT TARGET WILL BE INCREASED BY 50 SUBJECTS TO A TOTAL TARGET OF 220 SUBJECTS.AXOGEN INC - EXPECTS TO COMPLETE ENROLLMENT DURING SUMMER OF 2020. 

Company Quote

21.33
0.32 +1.52%
24 May 2019